This Article Full Text Full Text (PDF) A retraction has been published Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager NURSA Molecule Pages Link Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wang, L. Articles by Moore, D. D. Search for Related Content PubMed PubMed Citation Articles by Wang, L. Articles by Moore, D. D.

Orphan Receptor Small Heterodimer Partner Is an Important Mediator of Glucose Homeostasis

Departments of Medicine and Pharmacology (L.W., J.H.), University of Kansas Medical Center, Kansas City, Kansas 66160; Departments of Molecular and Cellular Biology (P.S., L.C., D.D.M.) and Medicine (M.H., L.C., A.S.R.), Baylor College of Medicine, Houston, Texas 77030; Joslin Diabetes Center, Harvard Medical School (R.N.K.), Boston, Massachusetts 02215; and Department of Internal Medicine (Y.K., K.P., I.L.), Keimyung University School of Medicine, Daegu 700-712, Korea

Address all correspondence and requests for reprints to: Li Wang, Departments of Medicine and Pharmacology, University of Kansas Medical Center, Kansas City, Kansas 66160. E-mail: lwang2{at}kumc.edu.

The orphan receptor small heterodimer partner (SHP; NROB2) is a transcriptional repressor that inhibits nuclear receptor signaling in diverse metabolic pathways. Here, we report that SHP^–/– mice exhibited hypoinsulinemia with age, which was associated with increased peripheral insulin sensitivity and increased response of isolated islets to glucose stimulation, yet maintain normal levels of blood glucose. Deficiency in SHP function resulted in up-regulation of glucose transporter 4 mRNA and glucose uptake in muscles, and overexpression of SHP in C2C12 cells inhibited both basal and peroxisomal proliferator-activated receptor (PPAR) coactivator-1-stimulated glucose transporter 4 expression and glucose uptake. SHP^–/– hepatocytes showed markedly decreased basal glucose production in cultures, and SHP^–/– livers had increased glycogen stores and were more sensitive to insulin inhibition of glucose output, which were concomitant with decreased expression for PPAR1, fatty acid translocase, glucose-6-phosphatase, and phosphoenol/pyruvate carboxykinase, and increased mRNAs for glucokinase and pyruvate kinase. In white fat, SHP deficiency resulted in up-regulation of genes involved in insulin sensitizing, including PPAR2 and adiponectin. We show that, at the transcriptional level, SHP directly represses adiponectin promoter activity by PPAR/liver receptor homolog-1. The results suggest that the increases in insulin sensitivity through multiple signaling pathways in muscle, liver, and fat, with an increase in islet secretory function, represent the complex mechanism whereby SHP deficiency leads to improvement in insulin sensitivity, secretion, and diabetes.

NURSA Molecule Pages Link:

Nuclear Receptors:   SHP  |  PPARγ  |  LRH-1

This article has been cited by other articles:

				P. B. Hylemon, H. Zhou, W. M. Pandak, S. Ren, G. Gil, and P. Dent Bile acids as regulatory molecules J. Lipid Res., August 1, 2009; 50(8): 1509 - 1520. [Abstract] [Full Text] [PDF]

				J. Miao, Z. Xiao, D. Kanamaluru, G. Min, P. M. Yau, T. D. Veenstra, E. Ellis, S. Strom, K. Suino-Powell, H. E. Xu, et al. Bile acid signaling pathways increase stability of Small Heterodimer Partner (SHP) by inhibiting ubiquitin-proteasomal degradation Genes & Dev., April 15, 2009; 23(8): 986 - 996. [Abstract] [Full Text] [PDF]

				S. Bhatnagar, H. A. Damron, and F. B. Hillgartner Fibroblast Growth Factor-19, a Novel Factor That Inhibits Hepatic Fatty Acid Synthesis J. Biol. Chem., April 10, 2009; 284(15): 10023 - 10033. [Abstract] [Full Text] [PDF]

				Q. T. Tran, L. Xu, V. Phan, S. B. Goodwin, M. Rahman, V. X. Jin, C. H. Sutter, B. D. Roebuck, T. W. Kensler, E.O. George, et al. Chemical genomics of cancer chemopreventive dithiolethiones Carcinogenesis, March 1, 2009; 30(3): 480 - 486. [Abstract] [Full Text] [PDF]

				P. Lefebvre, B. Cariou, F. Lien, F. Kuipers, and B. Staels Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation Physiol Rev, January 1, 2009; 89(1): 147 - 191. [Abstract] [Full Text] [PDF]

				V. Giguere Transcriptional Control of Energy Homeostasis by the Estrogen-Related Receptors Endocr. Rev., October 1, 2008; 29(6): 677 - 696. [Abstract] [Full Text] [PDF]

				R. B. Goldberg, V. A. Fonseca, K. E. Truitt, and M. R. Jones Efficacy and Safety of Colesevelam in Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Receiving Insulin-Based Therapy Arch Intern Med, July 28, 2008; 168(14): 1531 - 1540. [Abstract] [Full Text] [PDF]

				N. Nara, Y. Nakayama, S. Okamoto, H. Tamura, M. Kiyono, M. Muraoka, K. Tanaka, C. Taya, H. Shitara, R. Ishii, et al. Disruption of CXC Motif Chemokine Ligand-14 in Mice Ameliorates Obesity-induced Insulin Resistance J. Biol. Chem., October 19, 2007; 282(42): 30794 - 30803. [Abstract] [Full Text] [PDF]

				C. Marzolini, R. G. Tirona, G. Gervasini, B. Poonkuzhali, M. Assem, W. Lee, B. F. Leake, J. D. Schuetz, E. G. Schuetz, and R. B. Kim A Common Polymorphism in the Bile Acid Receptor Farnesoid X Receptor Is Associated with Decreased Hepatic Target Gene Expression Mol. Endocrinol., August 1, 2007; 21(8): 1769 - 1780. [Abstract] [Full Text] [PDF]

				M. Kobayashi, H. Ikegami, T. Fujisawa, K. Nojima, Y. Kawabata, S. Noso, N. Babaya, M. Itoi-Babaya, K. Yamaji, Y. Hiromine, et al. Prevention and Treatment of Obesity, Insulin Resistance, and Diabetes by Bile Acid-Binding Resin Diabetes, January 1, 2007; 56(1): 239 - 247. [Abstract] [Full Text] [PDF]